Welcome to our dedicated page for Ibex SEC filings (Ticker: IBEX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IBEX Limited (IBEX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered tools to help interpret them. As a Nasdaq-listed Bermuda company and emerging growth issuer, IBEX files a range of documents with the U.S. Securities and Exchange Commission that detail its operations, governance, and financial performance.
Key filings include Form 10-K and related annual reports, which present audited financial statements, risk factors, and management’s discussion of results for the fiscal year. Quarterly results and updates are frequently communicated through Form 8-K, where ibex furnishes press releases covering revenue, net income, adjusted net income, adjusted EBITDA, and earnings per share, as well as guidance ranges for future periods.
Investors can also review proxy materials such as the DEF 14A, which describe the board structure, director independence, committee composition, executive compensation programs, long-term incentive plans, and changes in status such as the transition away from controlled company exemptions. Other 8-K filings address governance developments, including the formation of a formal Nominating Committee and related board decisions.
Stock Titan enhances these filings with AI-powered summaries and explanations that highlight important sections, clarify technical language, and surface items that may matter to shareholders, such as governance changes, compensation plans, or capital allocation decisions. Real-time updates from EDGAR ensure that new IBEX filings, including Forms 3, 4, and 5 for insider transactions when available, appear promptly.
Use this page to explore IBEX’s historical and current SEC record, understand how management presents its strategy and performance, and quickly grasp the implications of lengthy documents through AI-generated insights.
Jones John William reported acquisition or exercise transactions in this Form 4 filing.
IBEX Ltd director John William Jones received an equity award of 2,250 common shares through restricted stock units. The RSUs carry a right to one common share each at no cash cost. The award vests 25% on July 1, 2026 and 25% annually for three additional years, contingent on his continued service. Following this grant, his direct ownership totals 15,244 common shares.
IBEX Ltd director Zhuang Mingzhe acquired 2,083 common shares through a stock award. The Form 4 shows a grant of restricted stock units (RSUs) at a price of $0.00 per share, increasing his direct holdings to 7,083 common shares.
The RSUs vest over four years. Twenty‑five percent vest on July 1, 2026, with an additional 25% vesting on each of the next three anniversaries, as long as he remains in continuous service on each vesting date.
Ballou-Aares Daniella reported acquisition or exercise transactions in this Form 4 filing.
IBEX Ltd director Daniella Ballou-Aares received an equity award of 2,083 common shares in the form of restricted stock units. The RSUs were granted at no cash cost and increase her direct holdings to 17,143 common shares. Twenty-five percent of the RSUs vest on July 1, 2026, with the remaining 75% vesting in equal annual installments over the following three years, contingent on her continued service.
McGinnis Patrick reported acquisition or exercise transactions in this Form 4 filing.
IBEX Ltd director Patrick McGinnis reported an equity award of 2,083 common shares in the form of restricted stock units (RSUs). The RSUs were granted at no cash price and increase his directly owned common shares to 6,863 after the transaction.
The footnote explains that each RSU represents a contingent right to receive one common share. Twenty-five percent of the RSUs vest on July 1, 2026, with the remaining 75% vesting in equal annual installments over the following three years, assuming he remains in continuous service on each vesting date.
Beck Fiona Elizabeth reported acquisition or exercise transactions in this Form 4 filing.
IBEX Ltd director Fiona Elizabeth Beck reported an equity award. She was granted 2,083 restricted stock units (RSUs), each representing a right to receive one common share at no cost. 25% of the RSUs vest on July 1, 2026, with the remaining 75% vesting in equal annual installments over the following three years, contingent on continued service. After this grant, her reported direct holdings total 13,583 common shares.
Batungbacal Karen reported acquisition or exercise transactions in this Form 4 filing.
IBEX Ltd director Karen Batungbacal reported an equity award of 2,083 common-share-based restricted stock units (RSUs). Each RSU represents the right to receive one common share. According to the vesting schedule, 25% of the RSUs vest on July 1, 2026, with an additional 25% vesting on each of the next three yearly anniversaries, as long as she remains in continuous service with the company.
Keen Shuja reported acquisition or exercise transactions in this Form 4 filing.
IBEX Ltd director Keen Shuja reported an equity award of 5,000 restricted stock units (RSUs). These RSUs give a contingent right to receive one common share for each unit. According to the grant terms, 25% of the RSUs vest on March 2, 2027, with an additional 25% vesting on the same date in each of the following three years, as long as Shuja remains in continuous service on each vesting date. The award was recorded at a price of $0.00 per share, reflecting that this is a compensation grant rather than an open-market purchase.
Dechant Robert Thomas reported acquisition or exercise transactions in this Form 4 filing.
IBEX Ltd reported that Chief Executive Officer Robert Thomas Dechant received an award of 18,000 Common Share–settled restricted stock units. These RSUs were granted at no cash cost and increase his directly held stake to 293,406 Common Shares, aligning his compensation further with shareholder interests.
According to the grant terms, 25% of the RSUs vest on July 1, 2026, with additional 25% installments vesting annually over the following three years, as long as he remains in continuous service. On each vesting date, IBEX will automatically withhold a portion of the resulting shares to cover tax withholding obligations in a non-discretionary transaction.
Greenwald Taylor C reported acquisition or exercise transactions in this Form 4 filing.
IBEX Ltd Chief Financial Officer Taylor C. Greenwald received a grant of 5,500 restricted stock units tied to IBEX common shares. Each RSU represents the right to receive one share. 25% vest on July 1, 2026, with additional 25% tranches vesting annually over the following three years, contingent on continued service. On each vesting date, IBEX will automatically withhold shares to cover tax obligations.
IBEX Ltd reported that Chief Operating Officer David Martin Afdahl acquired 4,400 common shares through a grant of restricted stock units. These RSUs carry no purchase price and represent a right to receive one share of common stock for each unit as they vest.
According to the award terms, 25% of the RSUs vest on July 1, 2026, with an additional 25% vesting each year for the next three years, as long as he remains in continuous service on each vesting date. Shares of common stock will be automatically withheld at each vesting to cover tax obligations. After this grant, he directly holds 157,302 common shares.